Stay updated on THALES: TicAgrelor & ASA in Acute Stroke Clinical Trial
Sign up to get notified when there's something new on the THALES: TicAgrelor & ASA in Acute Stroke Clinical Trial page.

Latest updates to the THALES: TicAgrelor & ASA in Acute Stroke Clinical Trial page
- Check3 days agoChange DetectedTHALES study page NCT03354429 shows the same core content as before, with no changes to primary outcomes, eligibility criteria, enrollment, or dates. The differences appear to be minor formatting/layout adjustments.SummaryDifference0.1% 
- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check25 days agoChange DetectedThe page is updated to reflect a new version (v3.2.0) and to add a prominent notice about government funding lapse and current operating status of NIH Clinical Center; the previous version reference (v3.1.0) was removed.SummaryDifference2% 
- Check32 days agoChange DetectedThe page now shows a newer version (v3.1.0) and removes several drug-safety topics, narrowing content coverage without adding new material elsewhere.SummaryDifference0.2% 
- Check46 days agoChange DetectedMéxico replaces Mexico (01090) and the revision becomes v3.0.2; Back to Top removed (minor UI change).SummaryDifference0.3% 
- Check53 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.1% 
- Check61 days agoChange DetectedThe webpage has undergone significant updates, including the addition of numerous locations and facility names, particularly in South Korea, Russia, and various European countries. Additionally, the study's total number of locations has been revised from 388 to 387.SummaryDifference23% 
Stay in the know with updates to THALES: TicAgrelor & ASA in Acute Stroke Clinical Trial
Enter your email address, and we'll notify you when there's something new on the THALES: TicAgrelor & ASA in Acute Stroke Clinical Trial page.